Apply to trial NCT06597565

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 2Drug trial

A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC

The purpose of the study is to determine the activity and safety of ACR-368 (prexasertib) in combination with gemcitabine in participants with Head and Neck Squamous Cell Carcinoma (HNSCC). Participants will receive the study drugs ACR-368 and a low dose of gemcitabine once every 2 weeks in 4-week cycles and will continue on treatment unless the disease deteriorates.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening